Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

AGA Releases New Guideline on Endoscopic Eradication Therapy for Barrett’s Esophagus

The American Gastroenterological Association (AGA) has released a new evidence-based Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia, providing updated recommendations for patients with Barrett’s esophagus, a precursor to esophageal cancer. Barrett’s esophagus is characterized by the presence of non-cancerous abnormal cells in the esophagus, which can progress to dysplasia and potentially cancer.

According to the guideline authored by Dr. Tarek Sawas from UT Southwestern, patients with high-grade dysplasia are recommended to undergo endoscopic therapy to remove pre-cancerous cells. However, for patients with low-grade dysplasia, the decision to remove or monitor the cells should be made collaboratively between doctors and patients after discussing the risks and benefits of treatment.

Endoscopic eradication therapy involves minimally invasive procedures like endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), followed by ablation techniques. The guideline emphasizes that most patients can be safely treated with EMR, which carries a lower risk of adverse events compared to ESD.

AGA recommends reserving ESD for cases suspected of deeper cancer invasion or for patients who have not responded to EMR. It is crucial for patients with Barrett’s esophagus to be treated and monitored by experienced endoscopists and pathologists specializing in Barrett’s neoplasia.

The guideline underscores the importance of a patient-centered approach, where treatment decisions are tailored to individual preferences and values, in addition to medical evidence. Surveillance is considered a viable option for patients who prioritize minimizing harms over uncertain benefits related to esophageal cancer mortality reduction.

By providing updated guidance on the management of Barrett’s esophagus, the AGA aims to improve patient outcomes and ensure that treatment decisions are informed and personalized. Patients with Barrett’s esophagus are encouraged to consult with their healthcare providers to determine the most appropriate course of action based on their specific circumstances.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *